Sun Pharmaceutical Industries Ltd. announcements
In the twelve months since 23 September 2025 Sun Pharmaceutical Industries Ltd. made 117 announcements to NSE under Regulation 30: 22 analysts/institutional investor meet/con. call updates, 19 general updates, 16 press release, 16 copy of newspaper publication, 5 investor presentation, 5 shareholders meeting. The latest, on 22 September 2026, was filed under investor presentation; the table carries the company's own summary of each and the PDF.
| Date | Category | What the company told the exchange | Filing |
|---|---|---|---|
| 22 September 2026 | Investor Presentation | Sun Pharmaceutical Industries Limited has informed the Exchange about Investor Presentation | |
| 11 September 2026 | General Updates | Intimation under Regulation 30 of SEBI LODR | |
| 9 September 2026 | General Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Incorporation of a Subsidiary Company | |
| 8 September 2026 | Credit Rating- New | Sun Pharmaceutical Industries Limited has informed the Exchange about International Credit Ratings | |
| 3 September 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet | |
| 1 September 2026 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated September 01, 2026, titled "Sun Pharma Participates in White House Signing Ceremony Highlighting U.S. Medicines Pricing and Access Commitments". | |
| 26 August 2026 | Copy of Newspaper Publication | Newspaper advertisements about Postal Ballot/E-Voting | |
| 25 August 2026 | Shareholders meeting | Notice of Postal Ballot | |
| 25 August 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet | |
| 17 August 2026 | General Updates | Update on Lipitor Antitrust Litigation | |
| 6 August 2026 | General Updates | Receipt of No-objection letters from the Stock Exchanges for Reclassification of Promoter Group | |
| 6 August 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Transcript | |
| 5 August 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet | |
| 5 August 2026 | Credit Rating | Sun Pharmaceutical Industries Limited has informed the Exchange about Credit Rating | |
| 1 August 2026 | Copy of Newspaper Publication | Sun Pharmaceutical Industries Limited has informed the Exchange about Copy of Newspaper Publication | |
| 31 July 2026 | General Updates | Voting Results and Scrutinizer Report of 34th AGM held on 31 July 2026 | |
| 31 July 2026 | Shareholders meeting | Outcome of 34th Annual General Meeting held on 31 July 2026 | |
| 31 July 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Link of Recording | |
| 31 July 2026 | General Updates | Conclusion of the Board Meeting held today, i.e., 31 July 2026 | |
| 31 July 2026 | Outcome of Board Meeting | Unaudited Standalone and Consolidated Financial Results for Q1 of FY 2026-27 | |
| 29 July 2026 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 29, 2026, titled "Sun Pharma receives approval to manufacture and market semaglutide in Brazil". | |
| 28 July 2026 | Copy of Newspaper Publication | Newspaper advertisement about opening of Special Window, for transfer of physical shares | |
| 27 July 2026 | General Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Update on Nidlegy | |
| 24 July 2026 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 24, 2026, titled "Sun Pharma Notes Organon Shareholder Approval for Proposed Acquisition". | |
| 15 July 2026 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 15, 2026, titled "Sun Pharma receives approval to manufacture and market generic semaglutide in South Africa". | |
| 14 July 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet | |
| 7 July 2026 | Investor Presentation | Sun Pharmaceutical Industries Limited has informed the Exchange about Investor Presentation | |
| 7 July 2026 | Copy of Newspaper Publication | Newspaper Publication | |
| 6 July 2026 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | Submission of Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 | |
| 6 July 2026 | Shareholders meeting | Sun Pharmaceutical Industries Limited has informed the Exchange regarding Notice of 34th Annual General Meeting to be held on 31 July 2026 along with the Annual Report for FY 2025-26 | |
| 26 June 2026 | Copy of Newspaper Publication | Sun Pharmaceutical Industries Limited has informed the Exchange about Copy of Newspaper Publication | |
| 25 June 2026 | Trading Window | Sun Pharmaceutical Industries Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 | |
| 20 June 2026 | General Updates | Acquisition of Innovcare Lifesciences Private Limited | |
| 16 June 2026 | Copy of Newspaper Publication | Newspaper Publication containing information about transfer of equity shares and unclaimed dividends to the Investor Education and Protection Fund (IEPF) Account | |
| 14 June 2026 | General Updates | Intimation under Regulation 30 of SEBI (LODR) Regulations 2015 | |
| 11 June 2026 | Record Date | Sun Pharmaceutical Industries Limited has informed the Exchange that Record date for the purpose of Final Dividend is 07-Jul-2026. | |
| 11 June 2026 | General Updates | Intimation of 34th Annual General Meeting and Record Date for Final Dividend and connected matters | |
| 29 May 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Transcript | |
| 27 May 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet | |
| 26 May 2026 | General Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Filing of Application for reclassification with stock exchanges | |
| 26 May 2026 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT (cosibelimab-ipdl)". | |
| 25 May 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet | |
| 23 May 2026 | Copy of Newspaper Publication | Sun Pharmaceutical Industries Limited has informed the Exchange about Newspaper Publication of Financial Results for year ended 31 March 2026 | |
| 22 May 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Link of Recording | |
| 22 May 2026 | General Updates | Additional Outcome of the Board Meeting | |
| 22 May 2026 | Dividend | Sun Pharmaceutical Industries Limited has informed the Exchange that Board of Directors at its meeting held on May 22, 2026, recommended Final Dividend of Rs. 5 per equity share. | |
| 22 May 2026 | General Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Financial Results and Recommendation of Dividend for FY 2025-26 | |
| 22 May 2026 | Outcome of Board Meeting | Sun Pharmaceutical Industries Limited has submitted to the Exchange, the Audited Financial Results for the quarter and year ended 31 March 2026. | |
| 20 May 2026 | Copy of Newspaper Publication | Sun Pharmaceutical Industries Limited has informed the Exchange about newspaper publication for special window for transfer of physical shares | |
| 18 May 2026 | Disclosure under SEBI Takeover Regulations | Dilip S. Shanghvi has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) and 31 (5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. | |
| 14 May 2026 | General Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Receipt of requests for reclassification of shareholder category | |
| 13 May 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet | |
| 12 May 2026 | Change in Director(s) | Sun Pharmaceutical Industries Limited has informed the Exchange regarding Change in Director(s) of the company. | |
| 8 May 2026 | General Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Completion and Result of Postal Ballot dated 07 April 2026 | |
| 7 May 2026 | Credit Rating | Sun Pharmaceutical Industries Limited has informed the Exchange about Credit Rating | |
| 5 May 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Transcript | |
| 27 April 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Link of Recording | |
| 27 April 2026 | Investor Presentation | Sun Pharmaceutical Industries Limited has informed the Exchange about Investor Presentation | |
| 27 April 2026 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated April 27, 2026, titled "Investor call to discuss the acquisition of Organon & Co.". | |
| 27 April 2026 | General Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Definitive Agreement to Acquire Organon | |
| 24 April 2026 | General Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Incorporation of a Subsidiary Company | |
| 17 April 2026 | Updates | Sun Pharmaceutical Industries Limited has informed the Exchange regarding Completion and Results of Postal Ballot dated 17 March 2026 | |
| 10 April 2026 | News Verification | The Exchange has sought clarification from Sun Pharmaceutical Industries Limited with respect to recent news item captioned Sun Pharma slips nearly 4% after $12 billion Organon deal enters final stage. The response from the Company is attached. | |
| 10 April 2026 | News Verification | The Exchange has sought clarification from Sun Pharmaceutical Industries Limited with respect to recent news item captioned Sun Pharma slips nearly 4% after $12 billion Organon deal enters final stage. The response from the Company is awaited. | |
| 8 April 2026 | Copy of Newspaper Publication | Sun Pharmaceutical Industries Limited has informed the Exchange about Copy of Newspaper Publication | |
| 7 April 2026 | Shareholders meeting | Sun Pharmaceutical Industries Limited has informed the Exchange regarding Notice of Postal Ballot for appointment of Ms. Satyavati Berera as an Independent Director | |
| 6 April 2026 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | Sun Pharmaceutical Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 | |
| 4 April 2026 | Appointment | Sun Pharmaceutical Industries Limited has informed the Exchange regarding Appointment of Independent Director | |
| 28 March 2026 | General Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Updates on Fibromun and Nidlegy | |
| 27 March 2026 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 27, 2026, titled "Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting". | |
| 25 March 2026 | Trading Window | Sun Pharmaceutical Industries Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 | |
| 21 March 2026 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India". | |
| 18 March 2026 | Copy of Newspaper Publication | Sun Pharmaceutical Industries Limited has informed the Exchange about Copy of Newspaper Publication | |
| 17 March 2026 | Shareholders meeting | Sun Pharmaceutical Industries Limited has informed the Exchange regarding Notice of Postal Ballot/E-voting | |
| 17 March 2026 | Updates | Sun Pharmaceutical Industries Limited has informed the Exchange regarding 'Shareholder Satisfaction Survey on RTA Services'. | |
| 16 March 2026 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis". | |
| 24 February 2026 | Investor Presentation | Sun Pharmaceutical Industries Limited has informed the Exchange about Investor Presentation | |
| 6 February 2026 | Copy of Newspaper Publication | Sun Pharmaceutical Industries Limited has informed the Exchange about the Newspaper Publication for the Special Window for the transfer of Physical Shares | |
| 4 February 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Transcript | |
| 3 February 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet | |
| 2 February 2026 | Updates | Sun Pharmaceutical Industries Limited has informed the Exchange regarding 'Sustainability Report for the financial year 2024-25'. | |
| 1 February 2026 | Copy of Newspaper Publication | Sun Pharmaceutical Industries Limited has informed the Exchange about Copy of Newspaper Publication | |
| 31 January 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Link of Recording | |
| 31 January 2026 | Change in Director(s) | Sun Pharmaceutical Industries Limited has informed the Exchange regarding Change in Director(s) of the company. | |
| 31 January 2026 | Dividend | Sun Pharmaceutical Industries Limited has informed the Exchange that Board of Directors at its meeting held on January 31, 2026, declared Interim Dividend of 11 per equity share. | |
| 31 January 2026 | Outcome of Board Meeting | Sun Pharmaceutical Industries Limited has submitted to the Exchange the Unaudited Financial Results for the quarter and nine months ended 31 December 2025. | |
| 23 January 2026 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated January 23, 2026, titled Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management, . | |
| 21 January 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet | |
| 20 January 2026 | Record Date | Sun Pharmaceutical Industries Limited has informed the Exchange that the Record date for the purpose of the Interim Dividend for FY 2025-26 is 05 February 2026 | |
| 20 January 2026 | News Verification | The Exchange has sought clarification from Sun Pharmaceutical Industries Limited with respect to recent news item captioned Sun Pharma Eyes Stronger US Presence With USD 10 Billion Organon Acquisition. The response from the Company is attached. | |
| 19 January 2026 | News Verification | The Exchange has sought clarification from Sun Pharmaceutical Industries Limited with respect to recent news item captioned Sun Pharma Eyes Stronger US Presence With USD 10 Billion Organon Acquisition. The response from the Company is awaited. | |
| 15 January 2026 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated January 15, 2026 | |
| 9 January 2026 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | Sun Pharmaceutical Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 | |
| 29 December 2025 | Trading Window | Sun Pharmaceutical Industries Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 | |
| 26 December 2025 | Investor Presentation | Sun Pharmaceutical Industries Limited has informed the Exchange about Investor Presentation | |
| 23 December 2025 | Copy of Newspaper Publication | Sun Pharmaceutical Industries Limited has informed the Exchange about Newspaper Advertisement | |
| 18 December 2025 | General Updates | Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 US FDA determines Baska facility inspection classification as OAI | |
| 2 December 2025 | Capacity addition | Sun Pharmaceutical Industries Limited has informed the Exchange about Approval of proposal for Greenfield Project | |
| 1 December 2025 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated December 01, 2025, titled "Sun Pharma introduces its global innovative drug, Ilumya® inIndia for treatment of moderate-to-severe Plaque Psoriasis". | |
| 26 November 2025 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated November 26, 2025 | |
| 22 November 2025 | Scheme of Arrangement | Sun Pharmaceutical Industries Limited has informed the Exchange about Effective date of Composite Scheme of Arrangement | |
| 17 November 2025 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated November 17, 2025, titled "AstraZeneca Pharma India Limited and Sun Pharma partner to help patients living with Hyperkalaemia in India". | |
| 12 November 2025 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release | |
| 12 November 2025 | Press Release | Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated November 12, 2025, titled "Philogen provides update on Fibromun clinical study developments". | |
| 11 November 2025 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Transcript | |
| 10 November 2025 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet | |
| 7 November 2025 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet | |
| 6 November 2025 | Copy of Newspaper Publication | Sun Pharmaceutical Industries Limited has informed the Exchange about Copy of Newspaper Publication | |
| 5 November 2025 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Link of Recording | |
| 5 November 2025 | Amendment to AOA/MOA | Sun Pharmaceutical Industries Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company. | |
| 5 November 2025 | Outcome of Board Meeting | Sun Pharmaceutical Industries Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025. | |
| 31 October 2025 | Copy of Newspaper Publication | Sun Pharmaceutical Industries Limited has informed the Exchange about Copy of Newspaper Publication | |
| 15 October 2025 | Analysts/Institutional Investor Meet/Con. Call Updates | Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet | |
| 14 October 2025 | Updates | Sun Pharmaceutical Industries Limited has informed the Exchange regarding 'ESG Overview for FY2024-25'. | |
| 8 October 2025 | Scheme of Arrangement | Sun Pharmaceutical Industries Limited has informed the Exchange about Approval of Composite Scheme of Arrangement by NCLT | |
| 7 October 2025 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | Sun Pharmaceutical Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 | |
| 24 September 2025 | Copy of Newspaper Publication | Sun Pharmaceutical Industries Limited has informed the Exchange about Newspaper Publication for the 100 Days Campaign - Saksham Niveshak |
Regulation 30 of SEBI's listing regulations requires a company to tell the exchange of material events; the category is the exchange's, the words are the company's own summary as filed, cut to a few lines, and the PDF is the full filing.
Source
Corporate announcements on nseindia.com for SUNPHARMA.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.